Stifel Financial
ATRA icon

Stifel Financial’s Atara Biotherapeutics ATRA Stock Holding History

Stifel Financial’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-499
Closed -$20.1K – 3285
2023
Q2 		$20.1K Sell
499
-641
-56% -$36.2K ﹤0.01% 3285
2023
Q1 		$82.6K Buy
1,140
+30
+3% +$2.91K ﹤0.01% 3201
2022
Q4 		$91.1K Sell
1,110
-39
-3% -$4.06K ﹤0.01% 3145
2022
Q3 		$109K Buy
1,149
+728
+173% +$81.8K ﹤0.01% 3096
2022
Q2 		$82K Buy
421
+10
+2% +$1.63K ﹤0.01% 3179
2022
Q1 		$96K Sell
411
-12
-3% -$3.82K ﹤0.01% 3260
2021
Q4 		$167K Sell
423
-13
-3% -$5.47K ﹤0.01% 3185
2021
Q3 		$195K Buy
436
+14
+3% +$5.02K ﹤0.01% 3140
2021
Q2 		$164K Sell
422
-10
-2% -$3.57K ﹤0.01% 3173
2021
Q1 		$155K Buy
+432
New +$191K ﹤0.01% 3072

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Stifel Financial's ATRA Position: Q3 2023 in Review

Stifel Financial sold out of Atara Biotherapeutics (ATRA) in Q3 2023, closing a stake of 499 shares — an estimated $20.1K sold.

Stifel Financial first reported a position in ATRA in Q1 2021 and held it in 10 quarters. The position peaked at $195K in Q3 2021. 109 funds tracked by Wall St. Rank hold ATRA as of Q3 2023.

  • Stifel Financial reported no remaining Atara Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Stifel Financial sold 499 Atara Biotherapeutics shares in Q3 2023, an estimated $20.1K.
  • Stifel Financial first reported a position in Atara Biotherapeutics in Q1 2021 and held it in 10 quarters.
  • Stifel Financial's Atara Biotherapeutics position peaked at $195K in Q3 2021.
  • 109 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2023.

Based on Stifel Financial's 13F filing for Q3 2023, filed 13 Nov 2023.